Calay News
Novo Nordisk, one of the world’s largest insulin manufacturers, has announced that it will be slashing the prices of several insulin drugs by up to 75% in the United States. This move comes after years of public outrage over the high cost of diabetes care and follows similar price cuts by other drugmakers.
Novo Nordisk will reduce the list price of its NovoLog insulin by 75% and cut the prices of Levemir and Novolin by 65%. The price changes will go into effect on January 1, 2024, and will cover insulins that come in vials and injection pens.
The list price for NovoLog will fall to $139.71 from $558.83 for a pack of five injection pens and to $72.34 from $289.36 for a vial. The company hopes that this move will make insulin more affordable for the millions of Americans who rely on it to manage their diabetes.
Novo Nordisk’s decision to cut prices is a significant step towards making diabetes care more accessible and affordable. It follows similar moves by other drugmakers, including Eli Lilly, which recently announced that it would cut the list price of its Humalog insulin by 50%.
The high cost of insulin has been a longstanding issue for many Americans, with some patients having to choose between paying for insulin and other essentials like rent and food. The high cost of insulin has also led to a rise in black market sales of the drug, putting patients at risk of receiving counterfeit or expired products.
Novo Nordisk’s decision to cut insulin prices is likely to have a significant impact on the healthcare industry, making diabetes care more affordable and accessible for millions of people. The move also highlights the importance of addressing the high cost of prescription drugs in the United States. The move follows similar price cuts by other drugmakers and highlights the importance of addressing the high cost of prescription drugs in the country. This decision is likely to have a significant impact on the healthcare industry and is a positive step towards improving access to essential medications.
